The Non-Financial Ledger: What You Actually Paid For

Andrew Donoho lives in Decatur, Illinois. He saw an ad for Hims. He went to the website. He read that the product was made with the same active ingredient as Ozempic and Wegovy. He filled out a health questionnaire. He typed in his credit card number. He was told, via email, that a licensed provider had approved his prescription. He never spoke to a single human being who had a medical degree. He purchased three vials in February 2025, then six more in April 2025. He was injecting an untested chemical compound into his body based on the word of an advertising campaign and a copy-pasted email.

Gloria Ferguson lives in Peoria, Illinois. She saw a Hims & Hers ad. She went to forhers.com. She read the same claim. She went through the same questionnaire. She entered her credit card number. She received the same automated approval message. She purchased five vials. She also never spoke to a doctor. At no point during the entire purchase process did any human being with medical training describe what was actually in those vials, what risks it carried, or why it was different from the brand-name drugs she believed she was essentially buying.

That is the product Hims & Hers designed. The entire pipeline from advertisement to injection was engineered to bypass the one thing that might have stopped either of these people: a real conversation with a real doctor who could have explained what “compounded semaglutide” actually is. The prescribers in this system do not counsel. They do not warn. They rubber-stamp a purchase decision that the customer already made, influenced exclusively by advertising, and send back a copy-paste message containing a claim that is itself false: that the medication has been “proven to reduce appetite and promote weight loss.” It has not been proven. Only Wegovy has been proven. Hims & Hers’s product has never been tested in a clinical trial.

The people who took this product are not naive. They are ordinary Americans navigating a healthcare system that makes prescription weight-loss medication nearly inaccessible to most people. Ozempic and Wegovy are famously expensive, frequently in shortage, and often not covered by insurance. Hims & Hers stepped into that gap and offered something that looked and sounded like the real thing, at a lower price, with a frictionless checkout. The messaging was everywhere: Super Bowl ads, Miley Cyrus, Kristen Bell, Rob Gronkowski, Jennifer Lopez. The message was simple and consistent. Same ingredient. Confidence to start your weight loss journey.

What they were not told: the compound in those vials was built using a cheaper chemical assembly process that introduces fragments of peptide molecules that do not exist in Ozempic or Wegovy. Those fragments are foreign to the human immune system. The immune system may attack them. And when it does, the consequences can include rash, fever, inflammation, and anaphylaxis. Worse, the immune response can learn to also attack authentic semaglutide drugs. Customers who took this product may have permanently compromised their ability to benefit from the real medications they were trying to access. There is no clinical study to tell us how often this happens, because Hims & Hers never ran one.

The cruelest part is that the people most likely to have been harmed this way may never know it. They may take Ozempic or Wegovy years from now and wonder why it doesn’t work for them, never knowing that a cheap synthetic knockoff pre-armed their immune system against it. That loss is not in any settlement. There is no line item for it.

Legal Receipts: What the Documents Actually Say

The following quotations come directly from the class action complaint (Case No. 1:26-cv-01954) and the cited regulatory filings. Every word below is sourced. Nothing is paraphrased.

“The semaglutide bulk drug substance used by compounders is not the same semaglutide used in [Novo Nordisk’s] FDA-approved medicines. [Novo Nordisk] manufactures its semaglutide in yeast using recombinant DNA technology, whereas the compounders use active pharmaceutical ingredients that are manufactured by chemical synthesis… For the purposes of this supplement, we will refer to the compounded products as containing ‘semaglutide,’ even though these bulk drug substances are meaningfully different from [Novo Nordisk’s] semaglutide.”

— Novo Nordisk, April 29, 2025 Letter to FDA

• This is the maker of Ozempic and Wegovy formally telling the FDA that compounders are selling something different and calling it by the same name. Novo Nordisk explicitly chose to use quotation marks around “semaglutide” when referring to compounded products, a deliberate signal that the name is being misapplied.
• Novo Nordisk does not sell its semaglutide to any third party. The raw ingredient Hims & Hers uses comes from an entirely separate supply chain, produced by a fundamentally different method, and has never been verified against the original by the FDA.

“Working with a licensed compounding pharmacy, Hims is able to provide medications to meet our patients’ unique needs. Hims offers compounded semaglutide, a GLP-1 injection with the same active ingredient as Wegovy and Ozempic. This differs from brand-name weight loss injections, which typically come in a preloaded injection pen. But don’t worry, Hims will show you exactly how to take your injection.”

— Hims & Hers FAQ Section, hims.com (archived July 2024)

• The phrase “same active ingredient as Wegovy and Ozempic” is the central lie in this lawsuit. It is demonstrably false, as confirmed by independent testing, Novo Nordisk’s own petitions to the FDA, and two peer-reviewed scientific articles.
• The FAQ deliberately frames the only difference as a delivery mechanism (pen vs. vial) while actively hiding the true differences: the manufacturing process, the additional peptide impurities, the absence of safety testing, and the lack of FDA evaluation. This is a textbook case of concealment by selective framing.

“While name-brand medications like Ozempic and Wegovy are currently in short supply, Hims also provides compounded GLP-1s formulated with the same active ingredient. This means you can start your weight loss journey with confidence.”

— Hims & Hers FAQ Section, hims.com (archived July 2024)

• This statement weaponizes the Ozempic shortage as a sales mechanism. It positions the compounded product as a confident, equivalent substitute specifically for people who cannot access the real drug, targeting the most vulnerable and least-informed segment of the market.
• “Start your weight loss journey with confidence” is a direct safety representation, implying the product is proven and safe. The product has never been tested in a clinical trial. The confidence on offer is fabricated.

“The medication I’m prescribing you is proven to reduce appetite and promote weight loss.”

— Automated “licensed provider” approval message sent to both plaintiffs, Hims & Hers (February 2025)

• This statement is false. Only Wegovy has been clinically proven for weight loss. Hims & Hers’s compounded product has never been the subject of a clinical study of any kind. The word “proven” here has zero scientific basis when applied to this specific product.
• Both plaintiffs received substantially identical versions of this message, confirming it is an automated copy-paste, not a personalized medical assessment. There was no individual clinical judgment involved. The “prescription” process functioned as an automated checkout approval layer, not a medical consultation.

FDA concluded that the “same active ingredient” statements “imply that your products are the same as an FDA-approved product when they are not,” so “these claims are false or misleading.”

— FDA Warning Letter to Hims & Hers Health, Inc., September 9, 2025

• This is the federal government’s drug regulator, in writing, calling Hims & Hers’s advertising false or misleading. The warning letter was sent more than a year after the product launched around May 2024, meaning consumers were exposed to confirmed false advertising for over a year before the FDA acted.
• The FDA issued separate warning letters for both the hims.com and forhers.com websites on the same day, meaning both sides of the business were found to be running the same deceptive claims simultaneously.

Societal Impact Mapping: Who Gets Hurt and How

Public Health

The health risks documented in this lawsuit are concrete, documented, and span from the immediate to the permanent. The product was injected by an unknown number of people across the United States, all of whom were told it was equivalent to an FDA-approved drug.

• Untested immunogenic impurities in every dose: Hims & Hers’s chemical synthesis process produces peptide fragments with missing, extra, or substituted amino acids. These fragments do not exist in Ozempic or Wegovy. When injected, they are recognized by the immune system as foreign. The FDA’s own guidance states that such impurities “create the potential for differences in immunogenicity or may otherwise affect the safety or effectiveness of a peptide drug product.”
• Risk of anaphylaxis and immune-mediated side effects: The complaint specifically documents that peptide impurities can trigger immune-mediated reactions including rash, flu-like symptoms, inflammation, and anaphylaxis. These are serious, potentially life-threatening reactions. No safety study has ever been conducted to establish the rate or severity of these reactions in Hims & Hers’s specific product.
• Cross-reactivity that may permanently compromise response to authentic GLP-1 drugs: If the immune system mounts a response to the novel peptide impurities, it can also learn to attack authentic semaglutide. Consumers who took this product may find that Ozempic or Wegovy is less effective or ineffective for them in the future, with no way to reverse that immune conditioning. This is an irreversible harm.
• Cross-reactivity with the body’s own natural GLP-1 hormone: The most severe documented risk is that the immune response could extend to the body’s endogenous GLP-1 peptide, the naturally occurring hormone that regulates blood sugar and appetite. Attacking your own GLP-1 system has serious, potentially permanent metabolic consequences. The complaint calls this “serious health consequences.” No clinical study exists to quantify this risk for Hims & Hers’s specific product.
• Benzyl alcohol added with no tested interactions: The Hims & Hers product contains benzyl alcohol, a chemical preservative not present in Ozempic or Wegovy. The complaint states that Hims & Hers has, upon information and belief, never tested whether benzyl alcohol has adverse effects in combination with the product’s unique active ingredient. Consumers were not informed of this additive.
• Cumulative harm from repeated injections over time: Even small amounts of novel peptide impurities can become clinically significant through repeated injections over weeks and months. The complaint notes that the concern is especially acute “particularly after repeated injections over time.” Both plaintiffs purchased multiple vials and took the product over an extended period.
• Precedent set by other dangerous peptide compounds: The FDA has already identified a list of peptide compounds with similar impurity profiles that “may present significant safety risks,” including BPC-157, Melanotan II, and Thymosin beta-4 fragment, among many others. The mechanism of harm is the same. The difference is that those compounds are restricted; Hims & Hers’s product was mass-marketed at Super Bowl scale.
• No doctor ever counseled these patients: Neither plaintiff, nor any member of the class, ever received a professional medical opinion on the risks of this product. The “licensed provider” system was designed to create the legal appearance of a prescription while functionally bypassing any real informed consent. The result is that people injected an untested substance into their bodies with no meaningful medical guidance.

Economic Inequality

This scheme exploited a specific economic and structural vulnerability: the inaccessibility of legitimate GLP-1 drugs for working-class Americans. Hims & Hers targeted people who could not afford or access the real medications and sold them a cheaper substitute disguised as equivalent.

• 100% out-of-pocket, zero insurance coverage: Hims & Hers does not accept health insurance or any government health programs. Every consumer paid the full price themselves. This means the financial burden fell entirely on individuals, with no third-party protection, and that the cost-benefit calculus was made by people who had no way to independently verify what they were buying.
• The product was priced to exploit the shortage gap: The complaint explicitly acknowledges that Ozempic and Wegovy are “currently in short supply,” and that Hims & Hers’s marketing directly invoked the shortage to sell its substitute. People who could not access legitimate medications due to cost or scarcity were the explicit target demographic.
• Consumers paid full price for a product worth far less: The complaint states that plaintiffs and class members either would not have purchased the product at all, or “would have paid far less for it,” had they known the truth. The economic harm is the gap between what was paid and what a fully informed consumer would have paid for an untested, unapproved, chemically synthesized compound with no clinical evidence.
• The telehealth loophole concentrated this harm in the consumer market: The complaint documents that compounding pharmacies operate under regulatory loopholes originally designed for small-scale, localized prescription adjustments. Modern internet infrastructure, global supply chains, and aggressive digital advertising turned that loophole into a mass-market pipeline. The people most harmed are those who lacked the financial or institutional resources to access legitimate pharmaceutical channels.
• Marketing spend aimed at maximum consumer capture: Hims & Hers advertised across television (including the Super Bowl), Facebook, Instagram, TikTok, YouTube, Reddit, Google Ads, radio, billboards, magazines, and newspapers. Celebrity influencers including Miley Cyrus, Jennifer Lopez, and Rob Gronkowski were paid to amplify the brand. This was a concentrated effort to reach as many ordinary consumers as possible with a false message, funded by the revenues those same consumers generated.
• Future medical costs borne by harmed consumers, not Hims & Hers: If any consumer develops an immune response, requires medical treatment, or finds legitimate semaglutide drugs permanently less effective due to immune cross-reactivity, they bear those costs. Hims & Hers pocketed the revenue. The downstream medical bills go to the same people who were misled into buying the product.

The “Cost of a Life” Metric

What Now? The Watchlist and How to Fight Back

This lawsuit is active. The defendants are publicly traded corporations. The regulators named in the source material have already issued formal findings. Here is what to watch and what to do.

Key Corporate Roles at Hims & Hers Health, Inc.

The complaint identifies these corporate entities as defendants. Named executives are not identified in the source material. These are the entities the lawsuit holds accountable:

• Hims & Hers Health, Inc.: Publicly traded, incorporated in Delaware, headquartered in San Francisco, California. Parent company and primary advertiser. Operated hims.com, forhers.com, and integrated smartphone apps carrying false advertising since approximately May 2024.
• Hims, Inc.: Co-defendant subsidiary. Also publicly traded, incorporated in Delaware, headquartered in San Francisco. Operated as part of the same advertising and distribution infrastructure.

Regulatory Watchlist

• FDA (Food and Drug Administration): Already issued formal warning letters on September 9, 2025 to both hims.com and forhers.com. The FDA has also received petitions from Novo Nordisk to place semaglutide on its list of products presenting demonstrable difficulties for compounding. Watch for FDA rulemaking on compounded GLP-1 products. FDA Commissioner has publicly criticized this advertising in JAMA (September 2025).
• FTC (Federal Trade Commission): Hims & Hers’s advertising practices fall squarely within FTC jurisdiction over deceptive trade practices in consumer advertising. The scale of this campaign, spanning TV, digital, social media, and celebrity endorsements, with a confirmed false central claim, is a textbook FTC enforcement target.
• DOJ / U.S. Attorneys: If the class action uncovers evidence that Hims & Hers knowingly and intentionally sold a misbranded drug product, potential criminal referrals to DOJ under the Federal Food, Drug, and Cosmetic Act become relevant.
• State Attorneys General (Illinois, California, New York): The complaint alleges violations of the Illinois Consumer Fraud and Deceptive Trade Practices Act (815 ILCS 505), California’s UCL and CLRA (Cal. Bus. & Prof. Code § 17200; Cal. Civ. Code § 1750), and New York GBL §§ 349-350. Attorneys general in all three states have independent enforcement authority.
• U.S. Senate: Senators Durbin and Marshall wrote a formal letter to the FDA on February 7, 2025, citing the Super Bowl ad and demanding action. Congressional oversight of telehealth drug advertising is active. Track Senate Commerce and HELP committees.

What You Can Do Right Now

• If you purchased Hims & Hers compounded semaglutide from approximately May 2024 onward, you may be a member of the putative class. The case is Donoho v. Hims & Hers Health, Inc., Case No. 1:26-cv-01954, N.D. Illinois. Contact an attorney to understand your options. ClassAction.org maintains a searchable database of class action lawsuits where this case is listed.
• Report your experience to the FDA’s MedWatch program (fda.gov/safety/medwatch) if you experienced any adverse health effects after using this or similar compounded GLP-1 products. Individual reports create the evidentiary record regulators need to act.
• File a complaint with the FTC at reportfraud.ftc.gov. Document the specific advertising you saw, the platform where you saw it, and the date. The FTC uses complaint data to identify enforcement priorities. Volume matters.
• Contact your state attorney general’s consumer protection office. In Illinois: illinoisattorneygeneral.gov. In California: oag.ca.gov. In New York: ag.ny.gov. These offices maintain consumer fraud complaint databases that directly inform enforcement decisions.
• Tell people in your community what this product actually is. The people most likely to have purchased this product are the same people who cannot afford the real medications. Peer-to-peer information travels farther in those communities than press releases. Share this article. Talk to people. The advertising budget that built this scheme runs into the tens of millions. The most effective counter is the truth, spread widely and specifically.
• If you have medical concerns about a product you injected, see a doctor or immunologist and disclose that you used a chemically synthesized compounded GLP-1 product. Request that your provider document any relevant immune responses in your medical record. This documentation protects you and contributes to the public health record.